We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+2.32%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.92B
AUM Growth
+$79.1M
Cap. Flow
-$672M
Cap. Flow %
-22.98%
Top 10 Hldgs %
45.84%
Holding
68
New
6
Increased
13
Reduced
17
Closed
13
Avg Time Held
5 quarters
Top 10 Avg Time Held
3 quarters
Top 20 Avg Time Held
3.3 quarters

Top Buys

Rank Stock Value
1
CAI icon
Caris Life Sciences
CAI
+$197M
2
KRYS icon
Krystal Biotech
KRYS
+$48M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$39.7M
4
INSP icon
Inspire Medical Systems
INSP
+$31.9M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$29.2M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$65.9M
2
BPMC icon
Blueprint Medicines
BPMC
+$38.9M
3
IRTC icon
iRhythm Holdings
IRTC
+$33.1M
4
BCAX icon
Bicara Therapeutics
BCAX
+$28.2M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 71.51%
2 Miscellaneous 28.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CAI icon
1
Caris Life Sciences
CAI
$8.67B
$195M 6.69%
+7,316,142
New +$197M
2025 Q2
0 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$13.7B
$146M 4.99%
1,160,425
-31,500
-3% -$3.61M
2023 Q1
9 quarters
XENE icon
3
Xenon Pharmaceuticals
XENE
$3.26B
$113M 3.86%
3,605,029
+895,154
+33% +$29.2M
2022 Q4
10 quarters
ARGX icon
4
argenx
ARGX
$52B
$107M 3.67%
194,491
+33,642
+21% +$19.5M
2023 Q4
6 quarters
KRYS icon
5
Krystal Biotech
KRYS
$9.57B
$100M 3.42%
727,811
+327,067
+82% +$48M
2022 Q4
10 quarters
ALGN icon
6
Align Technology
ALGN
$10.1B
$94M 3.22%
496,730
-33,800
-6% -$5.97M
2022 Q4
10 quarters
LEGN icon
7
Legend Biotech
LEGN
$3.8B
$90.2M 3.09%
2,542,104
-435,847
-15% -$14.1M
2022 Q4
10 quarters
NUVL icon
8
DELISTED
Nuvalent
NUVL
$89.7M 3.07%
1,175,876
+334,931
+40% +$24.5M
2024 Q4
2 quarters
CGON icon
9
CG Oncology
CGON
$5.46B
$85.4M 2.92%
3,283,317
– –
2024 Q1
5 quarters
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.04B
$68.3M 2.34%
5,210,831
+2,752,023
+112% +$39.7M
2024 Q3
3 quarters
INSP icon
11
Inspire Medical Systems
INSP
$1.98B
$67.8M 2.32%
522,410
+220,000
+73% +$31.9M
2023 Q3
7 quarters
APGE icon
12
DELISTED
Apogee Therapeutics
APGE
$64.2M 2.2%
1,478,512
-61,850
-4% -$2.35M
2023 Q3
7 quarters
GKOS icon
13
Glaukos
GKOS
$9.82B
$62.3M 2.13%
603,414
-21,021
-3% -$1.97M
2022 Q4
10 quarters
DHR icon
14
Danaher
DHR
$158B
$61.1M 2.09%
309,339
– –
2025 Q1
1 quarter
TMO icon
15
Thermo Fisher Scientific
TMO
$249B
$54.8M 1.88%
135,233
+7,500
+6% +$3.14M
2024 Q4
2 quarters
ISRG icon
16
Intuitive Surgical
ISRG
$147B
$48.7M 1.67%
89,600
+1,600
+2% +$837K
2024 Q1
5 quarters
IRTC icon
17
iRhythm Holdings
IRTC
$3.47B
$46.2M 1.58%
300,029
-256,362
-46% -$33.1M
2022 Q4
10 quarters
ADPT icon
18
Adaptive Biotechnologies
ADPT
$4.12B
$45M 1.54%
3,863,107
-940,687
-20% -$8.54M
2025 Q1
1 quarter
GH icon
19
Guardant Health
GH
$22B
$43.6M 1.49%
837,800
-489,527
-37% -$21.9M
2023 Q2
8 quarters
ATEC icon
20
Alphatec Holdings
ATEC
$1.61B
$40.4M 1.38%
3,635,172
-624,257
-15% -$7.17M
2024 Q2
4 quarters
SYRE icon
21
Spyre Therapeutics
SYRE
$7.36B
$38.6M 1.32%
2,578,404
– –
2023 Q4
6 quarters
VKTX icon
22
Viking Therapeutics
VKTX
$3.28B
$38.1M 1.3%
1,437,555
+1,600
+0.1% +$42.1K
2024 Q1
5 quarters
TMDX icon
23
Transmedics
TMDX
$2.62B
$34.2M 1.17%
255,048
-599,836
-70% -$65.9M
2024 Q4
2 quarters
PEN icon
24
Penumbra
PEN
$12.6B
$33.3M 1.14%
129,628
+19,500
+18% +$5.31M
2022 Q4
10 quarters
DYN icon
25
Dyne Therapeutics
DYN
$2.76B
$31.2M 1.07%
3,273,349
-347,995
-10% -$3.83M
2024 Q4
2 quarters
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2025 Portfolio in Review

As of Q2 2025, Braidwell held 68 positions worth $2.92B, up 2.8% from $2.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Braidwell withdrew a net $672M in Q2 2025, closing 13 positions and reducing 17 holdings. Its most notable exit was Blueprint Medicines, an estimated $38.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 67% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Caris Life Sciences worth $195M.

  • Braidwell's largest Q2 2025 buy was Caris Life Sciences: 7,316,142 shares worth $195M.
  • Braidwell added most to Krystal Biotech in Q2 2025, an estimated $48M increase.
  • Braidwell's biggest Q2 2025 reduction was Transmedics, cutting an estimated $65.9M.
  • Braidwell fully exited Blueprint Medicines in Q2 2025, selling an estimated $38.9M.
  • Braidwell's ten largest holdings make up 46% of its $2.92B portfolio in Q2 2025.
  • Braidwell opened 6 new positions and closed 13 in Q2 2025.
  • Braidwell's portfolio value rose 2.8% quarter-over-quarter to $2.92B.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.